NO20076508L - Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav - Google Patents

Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav

Info

Publication number
NO20076508L
NO20076508L NO20076508A NO20076508A NO20076508L NO 20076508 L NO20076508 L NO 20076508L NO 20076508 A NO20076508 A NO 20076508A NO 20076508 A NO20076508 A NO 20076508A NO 20076508 L NO20076508 L NO 20076508L
Authority
NO
Norway
Prior art keywords
prodrugs
methods
aminomethyl
trans
acycloxycarbamate
Prior art date
Application number
NO20076508A
Other languages
English (en)
Norwegian (no)
Inventor
Mark A Gallop
Bernd Jandeleit
Yunxiao Li
Noa Zerangue
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Publication of NO20076508L publication Critical patent/NO20076508L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20076508A 2005-06-20 2007-12-19 Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav NO20076508L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69262505P 2005-06-20 2005-06-20
PCT/US2006/023873 WO2007002013A2 (fr) 2005-06-20 2006-06-20 Prodrogues de carbamate d'acyloxyalkyle d'acide tranexamique, leurs procedes de synthese et leur utilisation

Publications (1)

Publication Number Publication Date
NO20076508L true NO20076508L (no) 2008-03-17

Family

ID=37460256

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076508A NO20076508L (no) 2005-06-20 2007-12-19 Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav

Country Status (15)

Country Link
US (4) US7351740B2 (fr)
EP (1) EP1919859B1 (fr)
JP (1) JP4938771B2 (fr)
KR (1) KR20080022203A (fr)
CN (1) CN101253148B (fr)
AT (1) ATE469880T1 (fr)
AU (1) AU2006262386B2 (fr)
CA (1) CA2612292C (fr)
DE (1) DE602006014694D1 (fr)
ES (1) ES2345784T3 (fr)
IL (1) IL188172A (fr)
NO (1) NO20076508L (fr)
NZ (1) NZ564468A (fr)
WO (1) WO2007002013A2 (fr)
ZA (1) ZA200800311B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050025825A1 (en) 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
MX2008011869A (es) * 2006-03-16 2008-12-03 Vertex Pharma Procedimientos e intermediarios para preparar compuestos estericos.
WO2009033069A1 (fr) * 2007-09-07 2009-03-12 Xenoport, Inc. Promédicaments de l'acamprosate esters de sulfonyle et néopentyle et esters simples d'acide pantoïque à libération par cyclisation, compositions et procédés d'utilisation
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US8299291B2 (en) * 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
WO2010017498A1 (fr) 2008-08-07 2010-02-11 Xenoport, Inc. Procédés de synthèse de carbonates de n-hydroxysuccinimidyle
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
US20110060040A1 (en) * 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
WO2011091164A1 (fr) 2010-01-22 2011-07-28 Xenoport, Inc. Formes galéniques orales ayant une charge élevée d'un promédicament d'acide tranexamique
US8597683B2 (en) * 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
DE202012012713U1 (de) * 2011-03-04 2014-01-23 Arstat, Inc. Intravaginale Arzneimittelabgabevorrichtung
WO2012141741A1 (fr) * 2011-04-12 2012-10-18 Arstat, Inc. Formulation de médicament de combinaison orale comprenant un médicament anti-inflammatoire non stéroïdien et une faible dose complémentaire d'acide tranexamique pour le traitement de douleur menstruelle accompagnée d'une perte excessive de sang menstruel
FI125336B (fi) * 2012-10-31 2015-08-31 Kone Corp Hissijärjestely
EP3082866B1 (fr) 2013-12-16 2024-08-14 The University Of British Columbia Particules auto-alimentées pour la propulsion à travers des liquides aqueux fluides
US20190083386A1 (en) * 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Methods and formulations for transdermal administration of buffering agents
WO2020074160A1 (fr) 2018-10-10 2020-04-16 Curovir Ab Dérivés de pyrimidine ou de pyridazine condensés en tant qu'agents antiviraux
JP2020090453A (ja) * 2018-12-05 2020-06-11 ポーラ化成工業株式会社 日焼け抑制用組成物
KR102670655B1 (ko) * 2020-08-13 2024-05-29 난징 헤론 파마슈티컬 사이언스 앤 테크놀로지 컴퍼니 리미티드 이부프로펜 에스테르계 전구약물, 약학적 조성물 및 제조방법과 응용
CN116710440B (zh) * 2020-12-31 2025-10-28 赛诺哈勃药业（成都）有限公司 一种纤溶酶抑制剂、其制备方法及应用
CN114728882B (zh) * 2021-06-29 2024-08-23 南京海融医药科技股份有限公司 一种布洛芬酯衍生物及其乳状制剂

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3499925A (en) 1964-03-23 1970-03-10 Daiichi Seiyaku Co Process for the production of trans-4-aminomethylcyclohexane - 1 - carboxylic acid
GB1364672A (en) 1971-06-09 1974-08-29 Beecham Group Ltd Penicillins
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4048222A (en) 1974-03-04 1977-09-13 Kureha Kagaku Kogyo Kabushiki Kaisha Process for preparing trans-4-aminomethyl-cyclohexane-1-carboxylic acid
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
JPS51138651A (en) 1975-05-27 1976-11-30 Kureha Chem Ind Co Ltd Process for pr eparing trans-4-aminomethyo-cyclohexane
US4055580A (en) 1975-08-22 1977-10-25 Rorer Italiana S.P.A. Derivatives of aminomethylcyclohexanecarboxylic acid
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4290905A (en) 1979-12-26 1981-09-22 Kabushiki Kaisha Suwa Seikosha Ester compound
ATE12224T1 (de) 1981-11-17 1985-04-15 Kabivitrum Ab Verbindungen mit antifibrinolytischer wirksamkeit.
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4426391A (en) 1982-09-15 1984-01-17 Merck & Co., Inc. [(Alkoxycarbonyl)oxy]alkyl esters of methyldopa
IL67445A (en) 1982-12-09 1985-11-29 Teva Pharma Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
EP0416689B1 (fr) 1989-09-06 1995-11-29 Merck & Co. Inc. Acyloxyméthyl esters d'acides bisphosphoniques comme inhibiteurs de la résorption osseuse
GB9001405D0 (en) 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE69316681T2 (de) 1992-08-27 1998-05-14 Shiseido Co Ltd Äusserliche, auf der Haut anzuwendende Depigmentierungsmittel enthaltende Zusammensetzung
SE9300013L (sv) * 1992-12-30 1994-07-01 Kabi Pharmacia Ab Nytt förfarande och mellanprodukter för framställning av pro- läkemedel
JPH07165555A (ja) * 1993-12-09 1995-06-27 Shiseido Co Ltd 皮膚外用剤
US5466811A (en) 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
JP3893439B2 (ja) 1994-12-19 2007-03-14 第一製薬株式会社 徐放性粒状製剤およびその製造方法
JP3483988B2 (ja) 1995-06-01 2004-01-06 株式会社資生堂 皮膚外用剤
JP3814881B2 (ja) 1996-08-07 2006-08-30 味の素株式会社 シクロヘキシルアミノ酸類の製造方法
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
HUP0202223A3 (en) 1999-07-15 2002-11-28 Lilly Co Eli Pseudomycin prodrugs, pharmaceutical compositions comprising thereof and their use
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (es) * 2001-06-11 2004-10-28 Xenoport Inc Formas de dosificacion de profarmacos de analogos de gaba administrados oralmente que tienen toxicidad reducida.
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6927036B2 (en) 2002-02-19 2005-08-09 Xero Port, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
ITMI20030882A1 (it) 2003-04-30 2004-11-01 Eni Spa Metodo per inibire l'acidificazione biologica di acque in contatto con materiali contenenti zolfo
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
US7860074B2 (en) * 2003-07-31 2010-12-28 Motorola, Inc. Method and apparatus for allocating communication resources
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
MXPA06004088A (es) * 2003-10-14 2006-06-27 Xenoport Inc Forma cristalina de un analogo del acido gamma-aminobutirico.
ES2405329T3 (es) * 2003-12-30 2013-05-30 Xenoport, Inc. Síntesis de profármacos de carbarnato de aciloxialquilo y productos intermedios de los mismos
US20050244495A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
EP1811986B1 (fr) * 2004-11-04 2014-03-26 XenoPort, Inc. Formes posologiques orales a liberation prolongee d'un promedicament de la gabapentine
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7332924B2 (en) * 2005-11-15 2008-02-19 Agere Systems, Inc. Embedded test circuitry and a method for testing a semiconductor device for breakdown, wearout or failure
US7770070B2 (en) * 2007-06-21 2010-08-03 Xerox Corporation Test automation via RFID technology
US8299291B2 (en) 2008-08-07 2012-10-30 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
WO2010017498A1 (fr) 2008-08-07 2010-02-11 Xenoport, Inc. Procédés de synthèse de carbonates de n-hydroxysuccinimidyle
WO2010047775A2 (fr) * 2008-10-20 2010-04-29 Xenoport, Inc. Méthodes de synthèse d'un promédicament de type ester de lévodopa
AU2010221167B2 (en) * 2009-03-06 2014-04-03 Xenoport, Inc. Oral dosage forms having a high loading of a gabapentin prodrug

Also Published As

Publication number Publication date
ZA200800311B (en) 2009-04-29
US20080153898A1 (en) 2008-06-26
ATE469880T1 (de) 2010-06-15
EP1919859B1 (fr) 2010-06-02
HK1117824A1 (en) 2009-01-23
US8372881B2 (en) 2013-02-12
JP2008546717A (ja) 2008-12-25
US20070027210A1 (en) 2007-02-01
WO2007002013A3 (fr) 2007-03-22
IL188172A0 (en) 2008-03-20
CN101253148A (zh) 2008-08-27
JP4938771B2 (ja) 2012-05-23
CA2612292A1 (fr) 2007-01-04
US7351740B2 (en) 2008-04-01
US20110009483A1 (en) 2011-01-13
ES2345784T3 (es) 2010-10-01
CA2612292C (fr) 2013-09-03
DE602006014694D1 (de) 2010-07-15
US7777070B2 (en) 2010-08-17
KR20080022203A (ko) 2008-03-10
WO2007002013A2 (fr) 2007-01-04
EP1919859A2 (fr) 2008-05-14
IL188172A (en) 2013-02-28
US7592369B2 (en) 2009-09-22
AU2006262386A1 (en) 2007-01-04
AU2006262386B2 (en) 2012-02-02
NZ564468A (en) 2011-05-27
CN101253148B (zh) 2013-01-02
US20100036148A1 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
IL188172A0 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
WO2005019163A3 (fr) Prodrogues a base de carbamate d'alkyle acyle, procede de synthese et utilisation
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
UA84048C2 (ru) Производные сульфонамида для лечения заболеваний, способ их получения (варианты), фармацевтическая композиция на их основе
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
CY1115940T1 (el) Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων
MX2010001242A (es) Profarmacos de canabidiol, composiciones que comprenden profarmacos de canabidiol y metodos para utilizar los mismos.
NO20063693L (no) Forbindelse og metode for anvendelse
UA109534C2 (uk) Співкристали трамадолу і коксибів
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
TR201909277T4 (tr) Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları.
DK1819227T3 (da) Farmaceutisk formulering af decitabin
ECSP045029A (es) Composiciones de valdecoxib de disgregación intraoral
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
EA200802020A1 (ru) Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
BR112014009910A2 (pt) formulações de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
WO2004100893A3 (fr) Methodes de traitement d'affections inflammatoires a l'aide de ct-3 ou de ses analogues
WO2008013860A3 (fr) Promédicaments d'alpha-acides aminés de type carbamate d'acyloxyalkyle, méthodes de synthèse et applications
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate
WO2006050472A3 (fr) Prodrogues d'acyloxyalkyl carbamate, et leurs procedes de synthese et d'utilisation
WO2006050471A3 (fr) Prodrogues d'acyloxyalkyl carbamate de l'acide 3-aminopropylsulfinique, et procedes de synthese et d'utilisation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application